Ten Programs To Watch Out For At ASCO
Executive Summary
The ASCO abstracts are out – and with them a scramble to see exactly what will be hitting the headlines in early June. Here, with the help of Sagient's BioMedTracker, Scrip takes a look at some of the more interesting studies due to be presented in Chicago in a couple weeks.
You may also be interested in...
CASTOR Propels J&J's Anti-CD38 Darzalex To Prime Position In Myeloma
Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.
Celator Shines At ASCO, Highlights Upside For Jazz
With proof of concept for its CombiPlex platform in the form of Phase III results for Vyxeos in acute myeloid leukemia, the $1.5bn purchase price paid by Jazz bought more than a promising late-stage asset.
Immuno-Oncology's Next Wave: Key Targets And Emerging Players
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.